Drugwatch.com survey links Depo-Provera to the highest rate of dissatisfaction as legal cases increase
ORLANDO, Fla., June 24, 2025 /PRNewswire/ — Drugwatch.com, a consumer watchdog health organization, has published findings from a survey of over 450 women (ages 18-70) on their birth control use. While more than 75% of respondents were happy with their current birth control method, nearly 1 in 4 have had to switch their birth control due to life-disrupting side effects.
In total, 35% of women surveyed experienced at least one side effect or injury related to their birth control. An important finding: over 53% of Depo-Provera users said that the birth control injection side effects either greatly or severely impacted their lives, which was significantly higher than other methods.
These findings come at a time of heightened concern and ongoing litigation around birth control options, including Depo-Provera. With 348 active Depo-Provera lawsuits and counting, this survey data gives a look into a widespread but underreported issue that affects many women.
“Women live very busy lives and sometimes one thing they don’t want to be worrying about on a daily basis is their contraception, …they want to have something they can set and forget,” said Vanessa Hux, OBGYN with Drugwatch, suggesting that Depo-Provera may not align with evolving patient priorities, especially compared to other contraceptives with better user control and less long-term disrupting side effects.
Read the full survey results here: https://www.drugwatch.com/birth-control-injury-survey/
About Drugwatch.com
Drugwatch.com is a consumer health and safety organization that provides expert-reviewed information on prescription drugs and medical devices. The site empowers consumers to make informed medical decisions and understand their legal rights. For more information, visit Drugwatch.com.
Contact: Cheyenne Rasmussen
Drugwatch.com
PR Coordinator
crasmussen@drugwatch.com
To speak to Dr. Vanessa Hux for further commentary, please contact Cheyenne Rasmussen at the email above.
Media Contact:
Michael Santiago
407-225-3268
397083@email4pr.com
SOURCE Drugwatch
